Ir(III) Diamine Transfer Hydrogenation Catalysts in Cancer Cells
Open Access
- 17 October 2024
- journal article
- research article
- Published by Wiley in ChemCatChem
- Vol. 17 (2)
Abstract
The development of catalytic metallodrugs is an emerging field that may offer new approaches to cancer chemotherapeutic design. By exploiting the unique properties of transition metal complexes, in‐cell catalysis can be applied to modulate the cellular redox balance as part of a multi‐targeting mechanism of action. We describe the synthesis and characterization of six coordinatively unsaturated iridium(III) diamine catalysts that are stable at physiological pH in aqueous solution. Reduction of the colorimetric substrate 2,6‐dichlorophenolindophenol by transfer hydrogenation under biologically compatible conditions achieved turnover frequencies up to 63 ± 2 h−1 and demonstrated that the source of hydride (sodium formate) is the limiting reagent, despite being in a 1000‐fold excess of the catalyst. The catalyst showed low in vivo acute toxicity in zebrafish embryos and modest in vitro potency towards cancer cells. When administered alone, the catalyst generated oxidative stress in cells (an effect that was conserved in vivo), but co‐treatment with a nontoxic dose of sodium formate negated this effect. Co‐treatment with sodium formate significantly enhanced catalyst potency in cancer cells (A2780 ovarian and MCF7 breast cancer cells) and drug‐resistant cells (A2780cis and MCF7‐TAMR1) but not in non‐tumorigenic cells (MRC5), demonstrating that a redox‐targeting mechanism may generate selectivity for cancer cells.Keywords
Funding Information
- Royal Society of Chemistry (E22‐1637945680)
- University of Birmingham
- Engineering and Physical Sciences Research Council (EP/P030572/1)
This publication has 54 references indexed in Scilit:
- In‐cell Catalysis by Tethered Organo−Osmium Complexes Generates Selectivity for Breast Cancer CellsChemBioChem, 2024
- Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitorsJBIC Journal of Biological Inorganic Chemistry, 2023
- In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) PhotocatalystsAngewandte Chemie International Edition, 2021
- Serum albumin: clinical significance of drug binding and development as drug delivery vehicle2021
- Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC–ICP–MSMonatshefte für Chemie - Chemical Monthly, 2018
- Easy To Synthesize, Robust Organo‐osmium Asymmetric Transfer Hydrogenation CatalystsChemistry – A European Journal, 2015
- The Potent Oxidant Anticancer Activity of Organoiridium CatalystsAngewandte Chemie International Edition, 2014
- Efficient and Rapid Synthesis of Chlorido‐Bridged Half‐Sandwich Complexes of Ruthenium, Rhodium, and Iridium by Microwave HeatingEuropean Journal of Inorganic Chemistry, 2013
- Reduction of Quinones by NADH Catalyzed by Organoiridium ComplexesAngewandte Chemie International Edition, 2013
- Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPRJBIC Journal of Biological Inorganic Chemistry, 2009